IMC Chicago
NTLA icon

IMC Chicago’s Intellia Therapeutics NTLA Stock Holding History

IMC Chicago’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.07M Buy
83,400
+41,600
+100% +$530K ﹤0.01% 3218
2025
Q4 		$376K Buy
+41,800
New +$575K ﹤0.01% 3661

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

IMC Chicago's NTLA Position: Q1 2026 in Review

IMC Chicago reduced its Intellia Therapeutics (NTLA) stake by 59% in Q1 2026, selling an estimated $231K and leaving 12,771 shares worth $164K. The position accounts for ﹤0.01% of the portfolio, ranked #5122.

IMC Chicago first reported a position in NTLA in Q4 2025 and has held it in 2 quarters since. The position peaked at $278K in Q4 2025. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • IMC Chicago held 12,771 shares of Intellia Therapeutics worth $164K as of Q1 2026.
  • IMC Chicago sold 18,132 Intellia Therapeutics shares in Q1 2026, an estimated $231K.
  • Intellia Therapeutics made up ﹤0.01% of IMC Chicago's portfolio in Q1 2026, its #5122 holding.
  • IMC Chicago first reported a position in Intellia Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • IMC Chicago's Intellia Therapeutics position peaked at $278K in Q4 2025.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.